Iovance's stock is down after receiving FDA feedback on application for new melanoma drugMarket Watch • 11/18/22
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced MelanomaGlobeNewsWire • 11/18/22
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/10/22
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 11/03/22
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022GlobeNewsWire • 10/24/22
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) TherapyGlobeNewsWire • 10/10/22
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum AcceleratesSeeking Alpha • 09/27/22
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced MelanomaGlobeNewsWire • 08/25/22